A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs PCM 075 (Primary)
  • Indications Carcinoma; Colon cancer; Head and neck cancer; Hepatocellular carcinoma; Leiomyosarcoma; Liposarcoma; Lung cancer; Ovarian cancer; Pancreatic cancer; Periampullary cancer; Prostate cancer; Skin cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 20 Jul 2017 Results published in the Investigational New Drugs
    • 25 May 2017 Data from this trial is being submitted for peer review publication by study investigators, as reported in a TrovaGene Media Release
    • 25 May 2017 Results published in the TrovaGene Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top